Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer

Date: February 22, 2011
Pages: 59
Price:
US$ 6,900.00 US$ 500.00
License [?]:
Publisher: The Assessment Group
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery
ID: O97897E2316EN
Leaflet:

Download PDF Leaflet

Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer
Treatment decisions for advanced stages of renal cell cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

Primary research for the oncology prescribing data that you are missing, directly from high-prescribing US oncologists: what they prescribe, when, and why. Case highlights include:
  • Older patient with retroperitoneal adenopathy and small lung nodules
    • Anemic patient with extremely high LDH levels
    • Patient with multiple comorbidities including heart and lung disease
    • Patient with one kidney and comorbidities
    This report allows you to:
    • Understand what occurs in the onologist’s office with actual patients
    • Access the most up-to-date prescribing trends
    • Gain actionable data for developing & improving market strategies
    • Pinpoint needs of your target audience
    • Design messages to advance brand performance
    • Focus resources to maximize the effectiveness of your budget
    • Understand where your competitor’s product fits
  • Executive Summary

    CHAPTER 1: INTRODUCTION

    Table 1. Treatment Options in Metastatic Breast Cancer

    CHAPTER 2: RESPONDENT DEMOGRAPHICS

    Table 2. Eligibility Criteria for Survey Participation
    Figure 2.1 Gender of Survey Respondents
    Figure 2.2 Years since Medical School Graduation
    Figure 2.3 Practice Settings
    Figure 2.4 Practices in NCI Cancer Centers
    Figure 2.5 Geographic Settings
    Figure 2.6 Survey Respondents by State’s Breast Cancer Mortality
    Figure 2.7 Number of Physicians in Practice Groups
    Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen

    CHAPTER 3: TREATMENT OF A PATIENT WITH TRIPLE NEGATIVE METASTATIC BREAST CANCER

    Figure 3.1Choice of chemotherapy regimen, triple negative metastatic breast cancer
    Figure 3.2 Single chemotherapy choices, triple negative metastatic breast cancer
    Figure 3.3 Combination chemotherapy choices, triple negative metastatic breast cancer
    Figure 3.4 Factors influencing treatment of triple negative metastatic breast cancer
    Figure 3.5 Confidence managing patient with triple negative metastatic breast cancer
    Figure 3.6 Other agents appropriate to include in treatment of triple negative metastatic breast cancer
    Figure 3.7 Treatment of progressive triple negative metastatic breast cancer
    Figure 3.8 Single chemotherapy agent, progressive triple negative metastatic breast cancer
    Figure 3.9 Combination chemotherapy, progressive triple negative metastatic breast cancer
    Figure 3.10 Barriers to optimal treatment of progressive triple negative metastatic breast cancer
    Figure 3.11 Changing therapy to manage neuropathy
    Figure 3.12 Recommended treatment of progressive triple negative metastatic breast cancer with BRCA-1 mutation
    Figure 3.13 Single agent chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation
    Figure 3.14 Combination chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation

    CHAPTER 4: TREATMENT OF PATIENT WITH TRIPLE POSITIVE METASTATIC BREAST CANCER

    Figure 4.1 Next step for patient with triple positive metastatic breast cancer
    Figure 4.2 Treatment of progressive disease, triple positive metastatic breast cancer
    Figure 4.3 Single chemotherapy choices for progressive triple positive metastatic breast cancer
    Figure 4.4 Combination chemotherapy, progressive triple positive metastatic breast cancer
    Figure 4.5 Factors influencing treatment of progressive triple positive metastatic breast cancer
    Figure 4.6 Treatment regimen for continued progression of triple positive metastatic breast cancer
    Figure 4.7 Decisions regarding the use of lapatinib in progressive triple positive metastatic breast cancer
    Figure 4.8 Management of progressive disease, triple positive metastatic breast cancer

    CHAPTER 5: PATIENT WITH ER/PR POSITIVE HER2NEU NEGATIVE METASTATIC BREAST CANCER

    Figure 5.1 Confidence managing patient with ER/PR positive HER2/neu negative metastatic breast cancer
    Figure 5.2 Other than analgesics, treatment of patient’s hip pain with ER/PR positive HER2/neu negative metastatic breast cancer
    Figure 5.3 Treatment with ER/PR positive HER2/neu negative metastatic breast cancer
    Figure 5.4 Factors influencing treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer
    Figure 5.5 Next systemic treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer

    CHAPTER 6: PATIENT WITH METASTATIC BREAST CANCER WITH MULTIPLE COMORBIDITIES

    Figure 6.1 Confidence managing patient with metastatic breast cancer with multiple comorbidities
    Figure 6.2 Barriers to managing patient, metastatic breast cancer with multiple comorbidities
    Figure 6.3 Treatment in addition to the aromatase inhibitor for patient’s metastatic breast cancer with multiple comorbidities
    Figure 6.4 Next treatment regimen for progressive metastatic breast cancer with multiple comorbidities
    Figure 6.5 Factors influencing treatment for progressive metastatic breast cancer with multiple comorbidities

    CHAPTER 7: SUMMARY

    Appendix A: Survey Instrument
    Skip to top


    Ask Your Question

    Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer
    Company name*:
    Contact person*:
    Phone/fax*:
    Email*:
    Request invoice
    Your enquiry:
    Please click on a Check Box below to confirm you are not a robot: